Questions? Call 800-624-6242
|
|
|
|
|
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Page 388
APPROVED DISEASE-MODIFYING MEDICATIONS
|
Generic Name
|
Trade Name
|
Company
|
Indication
|
Mechanism of Action
|
Potential Side Effects
|
|
Beta-Interferon-1a
|
Avonex, Rebifa
|
Biogen, Serono
|
RRMS
|
Beta-interferon-1a is believed to suppress the autoimmune destruction of myelin. Slows accumulation of disability and decreases the frequency of clinical exacerbations. Interferon-β-1a is involved in the regulation of activation, proliferation, migration, and suppressor cell function of T-cells, the modulation of the production of cytokines, including down-regulation of proinflammatory cytokines and up-regulation of inhibitory, antiinflammatory cytokines.
|
Flu-like symptoms, muscle aches, fever, chills and weakness, pain from intramuscular injection
|
|
Beta-Interferon-1b
|
Betaseron
|
Berlex Labs (Distributor)
Chiron (Manufacturer)
|
RRMS
|
Possesses both antiviral and immunoregulatory activities, mediated through interactions with specific cell receptors, which results in the expression of interferon-induced gene products.
|
Redness, pain and swelling and discoloration at injection site, flu-like symptoms, depression, anxiety, depersonalization, suicide attempts
|
|
|
|